VS 041
Alternative Names: VS-041Latest Information Update: 22 Jan 2024
At a glance
- Originator Vasa Therapeutics
- Class Antifibrotics; Heart failure therapies; Small molecules
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Heart failure